ABEO241220P12500
- 0.00
- 0.000.00%
Abeona Therapeutics Newsroom
Positive Outlook for Abeona Therapeutics: FDA Acceptance and Strategic Initiatives Reinforce Buy Rating
Earnings Week Ahead: NVDA, WMT, SNOW, TGT, BIDU, NIO, ZIM, and More
Abeona Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Abeona Therapeutics Inc: Current Cash and Cash Equivalents, Credit Facility Are Sufficient Resources to Fund Ops Into 2026
Abeona Therapeutics | 8-K: Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Express News | Abeona Therapeutics Q3 Cash & Investments USD 110 Million
Press Release: Abeona Therapeutics(R) Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Abeona Therapeutics 3Q Loss/Shr 63c >ABEO
Express News | Abeona Therapeutics Q3 Net Income USD -30.269 Million Vs. IBES Estimate USD -17.7 Million
Abeona Therapeutics Gets PDUFA Date for Its Epidermolysis Bullosa Treatment
Express News | Abeona Therapeutics Inc - May Receive Priority Review Voucher if Pz-Cel Approved
Express News | Abeona Therapeutics Inc - FDA Sets Pdufa Target Action Date of April 29, 2025
Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Express News | Abeona Therapeutics® Completes Pz-Cel Biologics License Application Resubmission to U.S. Food and Drug Administration
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
Abeona Therapeutics Price Target Maintained With a $18.00/Share by Cantor Fitzgerald
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)